Endothelium-mediated vasodilation during ACE inhibition

Area of Science:

• Cardiovascular Pharmacology
• Endothelial Function
• Renin-Angiotensin System

Background:

• Angiotensin-converting enzyme (ACE) inhibitors are established treatments for congestive heart failure, myocardial infarction, and hypertension.
• The precise mechanisms underlying the beneficial cardiovascular effects of ACE inhibitors remain incompletely understood.
• Endothelial-derived nitric oxide (NO) plays a crucial role in vascular homeostasis and vasodilation.

Purpose of the Study:

• To elucidate the mechanisms by which ACE inhibitors augment endothelium-derived nitric oxide release.
• To investigate the potentiation of bradykinin-induced vasodilation by ACE inhibitors in coronary arteries.
• To compare the chronic effects of ACE inhibitors and angiotensin receptor blockers on endothelial function.

Main Methods:

• Isometric force recordings in isolated bovine and human coronary artery rings.
• Assessment of vasodilation in response to bradykinin and its analogs in the presence and absence of ACE inhibitors.
• Experimental models in rats to evaluate chronic effects on endothelial function, including cyclosporin A treatment.

Main Results:

• ACE inhibitors potentiated bradykinin-induced relaxations in coronary arteries via a Bk2-receptor-dependent mechanism involving nitric oxide synthase.
• This potentiation was local and likely independent of bradykinin degradation.
• Chronic ACE inhibition or AT2 receptor antagonism prevented endothelial dysfunction induced by cyclosporin A in rats.

Conclusions:

• ACE inhibitors enhance bradykinin-mediated vasodilation through increased nitric oxide production by endothelial cells.
• These findings provide mechanistic insights into the cardiovascular benefits of ACE inhibitors.
• ACE inhibitors and AT2 receptor antagonists show potential in preserving endothelial function in specific clinical contexts.